These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 31993875)

  • 21. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):170-175. PubMed ID: 38687287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approach to Hypophosphatemic Rickets.
    Ackah SA; Imel EA
    J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
    Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rare diseases: a challenge in paediatric dentistry.
    Giuca MR
    Eur J Paediatr Dent; 2024 Sep; 25(3):171-171. PubMed ID: 39212455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia.
    Giralt M; Chocron S; Ferrer R; Ariceta G
    Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. X-linked hypophosphatemic rickets: an Italian experts' opinion survey.
    Emma F; Cappa M; Antoniazzi F; Bianchi ML; Chiodini I; Eller Vainicher C; Di Iorgi N; Maghnie M; Cassio A; Balsamo A; Baronio F; de Sanctis L; Tessaris D; Baroncelli GI; Mora S; Brandi ML; Weber G; D'Ausilio A; Lanati EP
    Ital J Pediatr; 2019 May; 45(1):67. PubMed ID: 31151476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
    Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
    Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease Manifestations and Complications in Dutch X-Linked Hypophosphatemia Patients.
    Bosman A; Appelman-Dijkstra NM; Boot AM; de Borst MH; van de Ven AC; de Jongh RT; Bökenkamp A; van den Bergh JP; van der Eerden BCJ; Zillikens MC
    Calcif Tissue Int; 2024 Mar; 114(3):255-266. PubMed ID: 38226986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
    Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
    Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Burosumab: Current status and future prospects.
    Goyal A; Tandon N
    Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study.
    Lo SH; Lachmann R; Williams A; Piglowska N; Lloyd AJ
    Qual Life Res; 2020 Jul; 29(7):1883-1893. PubMed ID: 32162120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
    Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
    Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypophosphatemic Rickets with R179W Mutation in FGFR23 Gene - A Rare But Treatable Cause of Refractory Rickets.
    Sandal S; Arora V; Verma IC
    Indian J Pediatr; 2021 Jan; 88(1):61-63. PubMed ID: 32415663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.
    Igaki JM; Yamada M; Yamazaki Y; Koto S; Izawa M; Ariyasu D; Suzuki E; Hasegawa H; Hasegawa Y
    Endocr J; 2011; 58(8):647-55. PubMed ID: 21597229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown.
    Baroncelli GI; Bertelloni S; Cosci O Di Coscio M; Tyutyusheva N; D'Elios S; Peroni D
    J Pediatr Endocrinol Metab; 2021 Jul; 34(7):905-910. PubMed ID: 33887813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
    Haffner D; Emma F; Eastwood DM; Duplan MB; Bacchetta J; Schnabel D; Wicart P; Bockenhauer D; Santos F; Levtchenko E; Harvengt P; Kirchhoff M; Di Rocco F; Chaussain C; Brandi ML; Savendahl L; Briot K; Kamenicky P; Rejnmark L; Linglart A
    Nat Rev Nephrol; 2019 Jul; 15(7):435-455. PubMed ID: 31068690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption.
    Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J
    J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.
    Trombetti A; Al-Daghri N; Brandi ML; Cannata-Andía JB; Cavalier E; Chandran M; Chaussain C; Cipullo L; Cooper C; Haffner D; Harvengt P; Harvey NC; Javaid MK; Jiwa F; Kanis JA; Laslop A; Laurent MR; Linglart A; Marques A; Mindler GT; Minisola S; Yerro MCP; Rosa MM; Seefried L; Vlaskovska M; Zanchetta MB; Rizzoli R
    Nat Rev Endocrinol; 2022 Jun; 18(6):366-384. PubMed ID: 35484227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.